ClinicalTrials.gg
RecruitingNCT05472168SNEEXUpdated Dec 20, 2023

Impact of Olfactory Odour StimulatioN on Energy EXpenditure

An interventional study of Olfactory Stimulation in Obesity, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2022, registered Jul 2022).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Obesity by University Hospital, Basel, Switzerland — 3 open to participants now, 4 under way, none of them phase 3. Obesity · University Hospital, Basel, Switzerland.

Planned enrollment
5th of 18
58 · median 36
Started
2022
with 1 other
No phase
14 of 20
2 open now
Registered
17th of 20
by date

Among the 20 studies in Obesity by University Hospital, Basel, Switzerland, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 with no phase, and was the 17th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 20 studies in Obesity by University Hospital, Basel, Switzerland are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Obesity by University Hospital, Basel, Switzerland, or all of them as a file.
02

Study summary

In this preliminary short-term study it is investigated, whether a short olfactory stimulation with distinct odours impacts energy expenditure in patients with obesity and lean patients.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age 18-55 years

      • Obesity ( ≥30 kg/m2) and Lean (BMI 18-25 kg/m2)
      • Written
      • Normosmia (defined by sniffing Sticks test)

Exclusion criteria

Exclusion Criteria:

    • Chronic or acute sinusitis

      • Surgical intervention of the nasal cavity or the paranasal sinus
      • Known allergy to odors used in the study
      • Smokers
      • Current illicit drug abuse including daily marijuana and cannabidiol (CBD) consumption (alcohol ≤2 drinks per day allowed)
      • Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease)
      • Diabetes mellitus
      • Treatment with insulin sensitizing drugs including Glucagon-like Peptide (GLP)-1 analogues within the last 3 months
      • History of neurodegenerative diseases, severe head trauma
      • Severe renal impairment (e.g. estimated \<30 ml/min/m2)
      • Known liver cirrhosis or other severe liver impairment
      • Use of any kind of decongestant more than twice a week
      • Use of cortisone-containing nasal spray within the last 3 months
      • Acute upper respiratory tract infection
      • Uncontrolled dysthyroidism
      • Uncontrolled hypertension
      • Regular use of psychopharmaceutic drugs
      • Study participants aims to start a new diet or exercise program during the study
      • Bariatric surgery
      • Pregnancy/Lactation
      • Onset of climacteric symptoms within one year (e.g. hot flashes and/or diaphoresis) OR initiation of hormonal replacement therapy in the last three months
      • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
      • Participation in an interventional study within the last 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
58 participants (estimated)

Study arms

  • Other
    Obese

    Age 18-55 years Obesity (BMI ≥30 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)

    Other: Olfactory Stimulation

  • Other
    Lean

    Age 18-55 years Lean (BMI 18-25 kg/m2) Written informed consent Normosmia (defined by sniffing Sticks test)

    Other: Olfactory Stimulation

Interventions

  • OtherOlfactory Stimulation

    Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.

    Also known as: Different odours

06

What researchers measure

Primary outcomes

  1. Change in Energy Expenditure

    change in energy expenditure as assessed via calorimetry after olfactory stimulation with different odours.

    Time frame: 6 hours

Secondary outcomes

  1. Energy Expenditure, Additional Odours

    Change in energy expenditure as assessed via calorimetry after olfactory stimulation with Different odours

    Time frame: 6 hours

  2. Heart Rate

    change in heart rate variability upon olfactory stimulation with different odors as assessed via continuous ECG

    Time frame: 6 hours

  3. Blood Pressure

    Change in blood pressure upon olfactory stimulation with different odors as assessed via a blood pressure cuff at the upper arm according to Riva Rocci

    Time frame: 6 hours

  4. Metabolic Parameters

    Change in metabolic blood parameters upon acute olfactory stimulation with different odours

    Time frame: 6 hours

  5. Glucose Levels

    change in interstitial fluid glucose levels upon olfactory stimulation with different odours

    Time frame: 6 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2024, 29 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 29 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Jul 25, 2022
StartActual
Jan 18, 2022
Primary completionEst.
Jun 30, 2024
CompletionEst.
Oct 30, 2024
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05472168
Responsible party
Katharina Timper (Principal Investigator, Prof. Dr. med., University Hospital, Basel, Switzerland) — Principal investigator
First posted
Jul 25, 2022
Start date
Jan 18, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Dec 20, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion